Intranet Fakultät für Chemie und Pharmazie

Prof. Dr. Robert Fürst


Ludwig-Maximilians-Universität München
Department Pharmazie
Butenandtstr. 5-13 Haus B
81377 München

Phone +49 89 2180 77172
Room-Nr. B4.024
Home page

Research Interests

  • Biogenic compounds and natural products
  • Cellular and molecular pharmacology
  • Inflammation, resolution of inflammation, angiogenesis, cancer
  • Endothelial cells, leukocytes, tumor cells

Short CV

  • Since 2023: W3 Professor (Chair), Pharmaceutical Biology, Department of Pharmacy, LMU Munich
  • 2012 - 2023: W3 Professor, Pharmaceutical Biology, Goethe University Frankfurt
  • 2011: Habilitation at the Faculty of Chemistry and Pharmacy, LMU Munich
  • 2005: PhD, LMU Munich

Key publications

  • Primke TF, Ingelfinger R, Elewa MAF, Macinkovic I, Weigert A, Fabritius MP, Reichel CA, Ullrich A, Kazmaier U, Burgers LD, Fürst R. The microtubule-targeting agent pretubulysin impairs the inflammatory response in endothelial cells by a JNK-dependet deregulation of the histone acetyltransferase Brd4. Cells; 2023: 12: 2112.
  • Burgers LD, Li Y, Michalakis S, Ciurus S, Zahler S, Müller R, Fürst R. The protein biosynthesis inhibitor vioprolide A evokes anti-angiogenic and pro-survival actions by targeting NOP14 and decreasing VEGF receptor 2- and Hippo-signaling. Biomed Pharmacother. 2022; 152: 113174.
  • Erkoc P, Schmitt M, Ingelfinger R, Bischoff-Kont I, Kopp L, Bode HB, Schiffmann S, Fürst R. Xenocoumacin-2 reduces protein translation and inhibits inflammation and angiogenesis-related processes. Biomed Pharmacother. 2021; 140: 111765.
  • Burgers LD, Luong B, Li Y, Fabritius M, Michalakis S, Reichel CA, Müller R, Fürst R. The natural product vioprolide A exerts anti-inflammatory actions through inhibition of its cellular target NOP14 and downregulation of importin-dependent NF-κB p65 nuclear translocation. Biomed Pharmacother. 2021; 144: 112255.